Dimethicone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dimethicone: From Gastrointestinal Gas Relief to Insomnia
One-Sentence Summary
Dimethicone is a silicone-based antifoaming agent that acts physically and is not absorbed after oral use. It is marketed in Singapore in a number of antacid and anti-flatulence products. The TxGNN model predicts it may be effective for insomnia, but 0 clinical trials and 0 publications support this direction, and no biological rationale has been identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 94.35% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 19 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Dimethicone is a silicone polymer that works as a surface-active antifoaming agent. It is not systemically absorbed after oral use, so it acts physically rather than pharmacologically.
Based on the data compiled for this report, no plausible mechanistic link exists between dimethicone and insomnia. It has no known activity on the main sleep-regulating pathways (GABA, orexin, histamine, melatonin). The high score of 0.94 appears to be a knowledge-graph artefact and has no supporting biological rationale.
The other top-ranked predictions are mainly cataract subtypes (such as immature, mature, senile, nuclear and cortical cataract) and severe nonproliferative diabetic retinopathy. They share the same weakness: no mechanism, no trials and no literature. Silicone oil is used surgically as an intraocular tamponade, and cataract is a known complication of that use. This is a device role rather than a therapeutic effect, so it does not support these indications. These predictions probably reflect proximity in the knowledge graph rather than pharmacology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Dimethicone has 19 valid single-ingredient registrations in Singapore and none have been cancelled. The records contain no approved indication text. The main authorisations are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09136P | RIDWIND BABY DROP | Emulsion | Not stated |
| SIN02382P | MYLOM DROPS 40 mg/0.6 ml | Solution | Not stated |
| SIN11621P | SIMCONE CHEWABLE TABLET 80 mg | Tablet | Not stated |
| SIN03333P | COLIMIX SYRUP | Syrup | Not stated |
| SIN16773P | ALVERSIME SOFT CAPSULES | Capsule | Not stated |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials, no literature and no plausible mechanism. Dimethicone is a non-absorbed, physically acting agent with no known effect on sleep pathways. Evidence is at the lowest level (L5).
To proceed, the following is needed:
- A credible mechanistic hypothesis explaining how a non-absorbed silicone could affect sleep
- Mechanism of action data from DrugBank
- Package insert warnings and contraindications from the HSA website
- Preclinical or clinical evidence for insomnia
- Assessment of route compatibility and the dosage forms required for any new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.